We are live on ! Find out more
DMAC icon

DiaMedica Therapeutics
DMAC

36 hedge funds and large institutions have $60.6M invested in DiaMedica Therapeutics in 2020 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 5

114% more capital invested

Capital invested by funds: $28.4M → $60.6M (+$32.2M)

33% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 9

9% more funds holding

Funds holding: 33 → 36 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3.86% less ownership

Funds ownership: 35.8% → 31.93% (-3.9%)

Holders
36
Holders Change
+3
Holders Change %
+9.09%
% of All Funds
0.64%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
11
Reduced
5
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.4M
2
EI
EAM Investors
California
+$602K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$446K
4
CA
Corriente Advisors
Texas
+$421K
5
SSA
Schonfeld Strategic Advisors
New York
+$362K

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$3.21M
2
MS
Maven Securities
Jersey
-$1.47M
3
CH
CVI Holdings
Delaware
-$1.17M
4
SCM
Stonepine Capital Management
Oregon
-$1.07M
5
DCM
DAFNA Capital Management
California
-$664K
Name Holding Trade Value Shares
Change 		Change in
Stake
FDCDDQ
26
Federation des caisses Desjardins du Quebec
Quebec, Canada
$61.1K +$1.26K +230 +4%
VFA
27
Valeo Financial Advisors
Indiana
$51K +$27.4K +5,000 New
US Bancorp
28
US Bancorp
Minnesota
$44K – – –
Wells Fargo
29
Wells Fargo
California
$21K +$170 +31 +1%
UBS Group
30
UBS Group
Switzerland
$9K +$5K +914 New
Royal Bank of Canada
31
Royal Bank of Canada
Ontario, Canada
$8K -$10.1K -1,853 -69%
CQS
32
Credential Qtrade Securities
$7.8K +$4.21K +769 New
GCM
33
Gables Capital Management
Florida
$5K – – –
NFSG
34
Newbridge Financial Services Group
Florida
$4K – – –
Federated Hermes
35
Federated Hermes
Pennsylvania
$1K -$3.05K -557 -89%
NCM
36
Nantahala Capital Management
Connecticut
– -$3.21M -756,193 Closed
MS
37
Maven Securities
Jersey
– -$1.47M -359,285 Closed
CH
38
CVI Holdings
Delaware
– -$1.17M -276,176 Closed
DCM
39
DAFNA Capital Management
California
– -$664K -156,529 Closed
WVP
40
Worth Venture Partners
New Jersey
– -$182K -42,887 Closed
MCM
41
Moore Capital Management
New York
– -$106K -25,000 Closed
APA
42
American Portfolios Advisors
New York
– -$10.6K -2,500 Closed
TRCT
43
Tower Research Capital (TRC)
New York
– -$6K -1,383 Closed
1
2

DMAC Hedge Fund Activity: Q4 2020 in Review

36 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q4 2020, worth a combined $60.6M — up 114% from $28.4M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new DMAC positions and 9 closed out — a net gain of 3 holders — while 11 added to existing stakes and 5 trimmed.

The largest buyer was Vanguard Group, adding an estimated $2.4M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $3.21M sold.

  • 36 institutional investors held DiaMedica Therapeutics (DMAC) as of Q4 2020, up from 33 in Q3 2020.
  • Funds reported $60.6M of DiaMedica Therapeutics stock for Q4 2020, up 114% quarter-over-quarter.
  • 12 funds opened new DiaMedica Therapeutics positions in Q4 2020 and 9 closed out, a net change of +3 holders.
  • The largest DiaMedica Therapeutics buyer in Q4 2020 was Vanguard Group, an estimated $2.4M added.
  • The largest DiaMedica Therapeutics seller in Q4 2020 was Nantahala Capital Management, an estimated $3.21M sold.

Based on aggregated 13F filings for Q4 2020.